Evidence map›Paper›PMID 31172535›Full record

ArticleJournal of clinical pharmacology2019

Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.

Ken Ogasawara, Kimberly MacGorman, Liangang Liu, Jian Chen, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Yan Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Population Pharmacokinetics of CC-122.Clinical pharmacology : advances and applications · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ken OgasawaraTranslational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.ORCID 0000-0002-4264-8927
Kimberly MacGormanTranslational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Liangang LiuBiostatistics and Statistical Programming, Celgene Corporation, Berkeley Heights, NJ, USA.
Jian ChenNon-Clinical Development, Celgene Corporation, Summit, NJ, USA.
Leonidas N CarayannopoulosTranslational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Simon ZhouTranslational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Maria PalmisanoTranslational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.
Yan LiTranslational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA.ORCID 0000-0001-7609-2683
Bristol-Myers Squibb (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Avadomide (CC-122) is a novel immunomodulatory drug that binds to cereblon, a member of the Cullin 4-RING E3 ubiquitin ligase complex. Avadomide has multiple pharmacologic activities including potent immune modulation, antiangiogenic, antitumor, and antiproliferative activity and is being evaluated as an oncology treatment for hematologic malignancies and advanced solid tumors. In vitro study has indicated that cytochrome P450 (CYP) 3A and CYP1A2 appear to be the major enzymes involved in the oxidative metabolism of avadomide. The effects of CYP3A inhibition/induction and CYP1A2 inhibition on the pharmacokinetics of avadomide in healthy adult subjects were assessed in 3 parts of an open-label, nonrandomized, 2-period, single-sequence crossover study. Following a single oral dose of 3 mg, avadomide exposure when coadministered with the CYP1A2 inhibitor fluvoxamine was 154.81% and 107.59% of that when administered alone, for area under the plasma concentration-time curve from time 0 to infinity (AUC

Indexed as

AdultArea Under CurveCross-Over StudiesCytochrome P-450 CYP1A2Cytochrome P-450 CYP1A2 InhibitorsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsDrug InteractionsFemaleHealthy VolunteersHumansMaleMiddle AgedPiperidonesQuinazolinones3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dioneCytochrome P-450 CYP1A2Cytochrome P-450 CYP1A2 InhibitorsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsPiperidonesQuinazolinonesRifampinavadomideCYP1A2CYP3Adrug-drug interactionsimmunomodulatory drug

Identifiers

PMID31172535
PMCPMC6851786
OpenAlexW2948884054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.